Evidence map›Paper›PMID 39966271›Full record

Trial reportEuropean radiology experimental2025

Intraindividual crossover comparison of gadobenate dimeglumine-enhanced and gadoxetate disodium-enhanced MRI for characterizing focal liver lesions.

Wenjie Tang, Yuanqiang Xiao, Sichi Kuang, Dailin Rong, Bingjun He, Luigi Grazioli, Shahid M Hussain, Jin Wang

Abstract readRandomized Controlled TrialComparative Study
In one paragraph

Trial report in European radiology experimental, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenjie Tang *Department of Radiology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, PR China.
Yuanqiang Xiao *Department of Radiology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, PR China.
Sichi KuangDepartment of Radiology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, PR China.
Dailin RongDepartment of Radiology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, PR China.
Bingjun HeDepartment of Radiology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, PR China.
Luigi GrazioliDepartment of Radiology, University of Brescia, Ospedale "Spedali Civili", Brescia, Italy.
Shahid M HussainDepartment of Radiology, Stony Brook University Hospital, Stony Brook, NY, USA.
Jin WangDepartment of Radiology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, PR China. wangjin3@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0002-7956-9579

Funding

China International Medical Foundation SKY Research Fund for Medical Imaging Z-2014-07-1912-15China International Medical Foundation SKY Research Fund for Medical Imaging Z-2014-07-2101Clinical Research Foundation of the 3rd Affiliated Hospital of Sun Yat-Sen University YHJH201901Guangdong Basic and Applied Research Foundation 2021A1515010582Key Research and Development Program of Guangdong Province 2019B020235002National Natural Science Foundation of China 82271973National Natural Science Foundation of China 91959118The 'Five Five' Project of the Third Affiliated Hospital of Sun Yat-sen University 2023WW103
6 · The paper itself

Abstract

backgroundGadobenate and gadoxetate are hepatobiliary magnetic resonance imaging (MRI) contrast agents. We intraindividually compared these two agents for the characterization of focal liver lesions (FLLs).

methodsA total of 140 adult subjects were randomized to undergo two 3-T MRI exams separated by 7-14 days, one with 0.05 mmol/kg gadobenate and one with 0.025 mmol/kg gadoxetate. For both exams, we acquired the same unenhanced T1-weighted, T2-weighted, and diffusion-weighted sequences, followed by contrast-enhanced T1-weighted sequences during the dynamic and hepatobiliary phases (HBP) (at 20 min for gadoxetate, at 120 min for gadobenate). Three experienced unaffiliated readers independently evaluated each exam in blinded, randomized order for lesion nature (benign/malignant) and specific lesion diagnosis. McNemar test, Wald tests. paired t-tests and κ statistics were used.

resultsA total of 208 FLLs (108 malignant and 100 benign) were confirmed at final diagnosis. Sensitivity and specificity for malignant/benign differentiation ranged from 91.6% to 99.1% and from 87.5% to 90.5% for gadobenate, and from 86.0% to 91.6% and from 79.7% to 83.6% for gadoxetate. Significantly (p ≤ 0.025) higher values for gadobenate were determined for all diagnostic performance parameters except for sensitivity and negative predictive value for one reader. Significantly (p < 0.001) greater accuracy and confidence for specific lesion diagnosis was achieved with gadobenate for two of three blinded readers. Interreader agreement for malignant/benign differentiation was better with gadobenate (κ = 0.91 versus κ = 0.72).

conclusionGadobenate was superior to gadoxetate for the differentiation and diagnosis of malignant and benign FLLs for two of three readers. Further confirmatory studies that include a wider representation of different types of FLLs are warranted. RELEVANCE STATEMENT: Better diagnostic performance and greater confidence in the characterization of FLLs with gadobenate might improve patient management decisions and timings, and potentially lead to better patient outcomes. KEY POINTS: Better diagnostic performance for the differentiation of FLLs was achieved with gadobenate for two of three readers. Reader confidence for lesion diagnosis was greater with gadobenate. Superior dynamic phase imaging with gadobenate was crucial for accurate lesion diagnosis.

Indexed as

Contrast MediaGadolinium DTPALiver NeoplasmsMagnetic Resonance ImagingMeglumineOrganometallic CompoundsAdultAgedCross-Over StudiesFemaleHumansMaleMiddle AgedProspective StudiesSensitivity and SpecificityContrast Mediagadobenic acidGadolinium DTPAgadolinium ethoxybenzyl DTPAMeglumineOrganometallic CompoundsContrast mediaGadobenic acidGadolinium ethoxybenzyl DTPALiver neoplasmsMagnetic resonance imaging

Identifiers

PMID39966271
PMCPMC11836252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.